Multiple murine BRafV600Emelanoma cell lines with sensitivity to PLX4032

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting BRAFV600E in an Inducible Murine Model of Melanoma

(2012) Anna I. Hooijkaas et al.   AMERICAN JOURNAL OF PATHOLOGY

Fibroblasts as architects of cancer pathogenesis

(2012) Timothy Marsh et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

(2012) Richard C. Koya et al.   CANCER RESEARCH

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma

(2012) Walburga Croteau et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

(2012) Anna Hooijkaas et al.   OncoImmunology

Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease

(2011) A. Vultur et al.   CLINICAL CANCER RESEARCH

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

(2010) J.-H. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

What Is a Good Model for Melanoma?

(2010) Meenhard Herlyn et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

(2009) Nathalie Dhomen et al.   CANCER CELL

Matrix metalloproteinase and G protein coupled receptors: Co-conspirators in the pathogenesis of autoimmune disease and cancer

(2009) Sarah M. Eck et al.   JOURNAL OF AUTOIMMUNITY

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis

(2009) J S Blackburn et al.   ONCOGENE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA